All US holdings of this investor are reported in this report. Request for Confidential Treatment (11/15/2021): Confidential Treatment Expired on 3/1/2022. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
This filing lists securities holdings reported on the form 13F filed on 11-15-2021 pursuant to a request for confidential treatment and for which confidential treatment expired on 03-01-2022.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
SANTIAGO DONOSO
CEO PROVIDA
Santiago, Chile
3/15/2022
Please note that this 13F Holdings Report filer is affiliated with MetLife Investment Management, LLC and Metropolitan Life Insurance Company who are also filing 13F Holdings Reports.Each entity is filing its own 13F Holdings Report because each entity has investment discretion over certain 13(f) securities reported. All three 13F Holdings Report filers are under commoncontrol of theirultimate parent, MetLife, Inc., who is filing a 13F Notice Report. 03.01.2022 amendment lists Provida 3Q 2021 holdings but was labelled incorrectly; and the new amendment includes the same positions with a corrected Cover Page to properly identify such positions as Provida 3Q 2021 Form 13F positions.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.